Targeting FDA user fees would leave agency gutted, experts say
Critics worry that the user fee program creates a conflict of interest between the FDA and pharmaceutical companies.
iQIYI Files Its Annual Report on Form 20-F
BEIJING, March 27, 2025 (GLOBE NEWSWIRE) -- iQIYI, Inc. (Nasdaq: IQ) (“iQIYI” or the “Company”), a leading provider of online entertainment ...